1. Introduction {#sec1}
===============

Chronic heart diseases lead to cardiac remodeling, a phenomenon that, besides structural changes, results in an impaired ability of cardiac myocytes to shift between nutrient substrate usage in order to adapt to energetic needs [@bib1]. Several cellular fuel gauges such as AMPK have been found to contribute to the regulation of synchronicity between tissue function and metabolic fluxes in the heart [@bib1]. However, studies from other systems suggest that the extracellular matrix (ECM) may also participate in the regulation of intracellular metabolism [@bib2]. The ECM may be relevant in different chronic heart diseases [@bib3], but how its components interact with intracellular signaling pathways to facilitate dynamic changes in heart metabolism is unknown.

We have recently focused on Tissue inhibitor of Metalloproteinase 3 (TIMP3), an ECM-bound protein, modulating metalloprotease and angiogenic receptors that is downregulated in human subjects and experimental models with metabolic and inflammatory disorders such as type 2 diabetes mellitus, atherosclerosis and heart failure [@bib4; @bib5; @bib6; @bib7; @bib8; @bib9; @bib10; @bib11; @bib12]. TIMP3 blocks the release of TNF-alpha and EGFR ligands (including TGF-alpha, amphiregulin) mediated by ADAM17. TIMP3 also blocks the activity of metalloproteases such as MMP9 and MMP14, which play a role in progression of heart disease. Finally, TIMP3 blocks the activation of VEGRF2 with a final effect to stabilize the angiogenic process to obtain a mature tube stabilization [@bib13; @bib14; @bib15; @bib16].

Previous work showed that loss of TIMP3 accelerates cardiovascular disorders including dilated and hypertrophic cardiomyopathies, abdominal aortic aneurysm and hypertension related vessel remodeling [@bib17; @bib18] mediated by TNF-alpha, Angiotensin II and metalloproteases.

Functional re-expression of TIMP3 via cell-based, vector delivery, or intravenous administration proved a protective role for TIMP3 against complications of myocardial infarction such as cardiac rupture, ischemic related cardiomyopathy and heart fibrosis and pressure overload, suggesting a putative therapeutic role for this protein to preserve tissue integrity, in part via its ability to maintain vasculature structure and mesenchymal stem cell functions [@bib19; @bib20; @bib21].

The role of TIMP3 in the context of cardiovascular remodeling is relatively unexplored when considering classical risk factors such as hypercholesterolemia, diabetes and hypertension. We have observed that increased levels of TIMP3 released from inflammatory cells partially protect from atherosclerosis progression in a combined genetic and dietetic model, the low density lipoprotein receptor knockout (LDLR^−/−^) mice fed a western diet [@bib10]. Observational studies in subjects with congestive heart failure suggested that TIMP3 might be deficient in the myocardial tissues [@bib22]. We recently described increased atherosclerosis at the aortic level in the ApoE^−/−^TIMP3^−/−^ mouse model. Here, we demonstrate that ApoE^−/−^TIMP3^−/−^ mice show decreased lifespan at the baseline and a reduced resistance to cardiac stress. To investigate this phenotype in more depth, we combined genetics, metabolomics and in vivo phenotypical analysis.

Collectively, metabolite profiling and gene and protein expression consistently suggested that the loss of TIMP3 leads to a perturbation of metabolic flexibility in the heart and arrhythmias, phenomena that may underlie the increased rates of cardiovascular death in this model independently from its atherosclerotic background.

2. Materials and methods {#sec2}
========================

2.1. Experimental animal procedures and metabolic tests {#sec2.1}
-------------------------------------------------------

All animal procedures were performed in accordance to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85--23, revised 1996), approved by the University Hospital of Tor Vergata Animal Care Facility and previously described [@bib23]. ApoE^−/−^ TIMP3^−/−^ mice have previously been described [@bib24]. The genotype was confirmed also assaying TIMP3 protein levels and activity of its substrate Matrix Metalloproteinase 9 ([Supplementary Figure S1A-B](#appsec3){ref-type="sec"}).

Animals were housed in shoebox-sized cages with free access to water and food on a 12 h day--night cycle. Where specified, animals were fed a Western diet (0.5% cholesterol, 45% calories from fat; Research Diets, New Brunswick, NJ) while all other animals received normal chow food (10% calories from fat; GLP Mucedola Srl, Settimo Milanese, Italy).

Glucose levels were measured in the fasting or fed state as indicated with an OneTouch Lifescan Glucometer. Plasma apelin was measured by ELISA (USCN Lifescience) after overnight fast. All tissues were collected in the fasting or the fed state as indicated and stored at −80. For fasting experiments, animals were fasted for 16 h.

Intraperitoneal glucose tolerance test (IPGTT) was performed after overnight fast. In brief, after a 16 h fast, animals were challenged with glucose (2 g/kg) injected intraperitoneally and blood was collected after 30, 60, 90 and 120 min and analyzed with a glucometer. Intraperitoneal insulin tolerance test (ITT) was performed after a 4 h fast. In brief, animals were challenged with insulin (0.75 U/kg) and blood was collected after 10, 30, 60 and 90 min and analyzed with a glucometer.

2.2. ECG telemetry {#sec2.2}
------------------

ECG recordings were taken in freely moving mice, monitored with a signal transmitter receiver connected to a data acquisition system (Data Sciences International, St Paul, USA.). Data were collected at 1,000 Hz and analyzed with ECG auto software Dataquest Ponemah 4.9 system (Data Sciences International). ECG was continuously recorded for 48 h per mice.

2.3. Acute myocardial infarction model {#sec2.3}
--------------------------------------

Ligation of the left anterior descending artery (LAD) was performed as a model of myocardial infarction as previously described [@bib25] and is explained in more detail in the supplementary data.

2.4. Indirect calorimetry {#sec2.4}
-------------------------

Indirect calorimetry was conducted in ApoE^−/−^TIMP3^−/−^ mice (n = 4) and ApoE^−/−^mice (n = 4) as well as in a second experiment after intraperitoneal apelin injections in ApoE^−/−^TIMP3^−/−^ and ApoE^−/−^ mice (n = 5--6 per group). All mice were acclimatized for 24 h to the metabolic cages. O2 consumption (VO2) and CO2 production (VCO2) were measured (TSE Systems, Germany) [@bib26] in mice at 15 min intervals during a 24 h period in the fed state as well as during a 12 h period in the fasting state. Respiratory exchange ratio (RER) (= VCO2/VO2) and lipid oxidation rates {= \[1.672 × (VO2 − VCO2)\]} were calculated.

2.5. Apelin supplementation {#sec2.5}
---------------------------

For apelin supplementation studies, Pyr-13 apelin was purchased from DBA Italia and resuspended in PBS. For intraperitoneal injections, a concentration of 0.1 μmol/kg was used as previously described [@bib27]. Control animals received matched volumes of PBS alone.

2.6. Gene expression analysis by qRT-PCR {#sec2.6}
----------------------------------------

Total RNA was isolated from liver, heart and muscle using Trizol reagent (Invitrogen Corp, Carlsbad, CA). Two micrograms of total RNA were reverse-transcribed into complementary DNA (cDNA) using the High Capacity cDNA Archive kit (Applied Biosystems, Foster City, CA). Quantitative real-time polymerase chain reaction was performed using an ABI PRISM 7700 System and TaqMan reagents (Applied Biosystems). Each reaction was performed in triplicate using standard reaction conditions and results were normalized by β-actin. Data were submitted to Gene Expression Omnibus (GEO) ([GSE53548](ncbi-geo:GSE53548){#intref0010}) \[NCBI tracking system \#16936641\].

2.7. Metabolomics {#sec2.7}
-----------------

For Metabolomics analysis, the serum of 6 male ApoE^−/−^ and 6 male ApoE^−/−^TIMP3^−/−^ was collected in the fasted state. Metabolomics assays were performed in service at Metabolon Laboratory and are described in detail in the supplementary data.

2.8. mRNA profiling and analysis {#sec2.8}
--------------------------------

Total RNA was isolated from hearts of ApoE^−/−^ and ApoE^−/−^TIMP3^−/−^ mice using Trizol reagent (Invitrogen Corp, Carlsbad, CA). mRNA sequencing was commercially performed at DNAVISION facility (Charleroi, Belgium). RNA libraries were prepared for sequencing using standard Illumina protocols. RNA-Sequencing profiling was performed by the Illumina HiSeq2000 platform. FastQC tool was used for the quality check of sequenced samples. For data analysis, a pipeline combining TopHat (<http://tophat.cbcb.umd.edu>) and Cufflinks (<http://cuffinks.cbcb.umd.edu>) was used to identify transcripts in each sample. TopHat uses the Bowtie aligner to produce alignment and to discover splice junctions. Cufflinks assembles transcripts, estimates their abundances, and tests for differential expression and regulation. Reads were aligned against the mouse reference genome (NCBIM37.60) and the identified transcripts were compared to those annotated in the reference genome. The metric used by Cufflinks to estimate the abundance of transcripts is the FPKM: Fragments Per Kilobase of exon per Million fragments mapped. For heat maps and hierarchical clustering MultiExperiment Viewer was used [@bib28]. Differential exons were computed by EdgeR package in Bioconductor. Data were submitted to GEO ([GSE53548](ncbi-geo:GSE53548){#intref0025}) \[NCBI tracking system \#16936641\].

2.9. Statistical analysis {#sec2.9}
-------------------------

Results of the experimental studies are mean ± SEM. Statistical analyses were performed using the unpaired Student\'s *t* test and one-way-ANOVA with GraphPAD Prism 6.0 if not otherwise specified. Survival analysis was performed according to the Kaplan Meier method and compared by using the Log-Rank test. Values of p \< 0.05 were considered statistically significant.

3. Results {#sec3}
==========

3.1. ApoE^−/−^TIMP3^−/−^ mice have increased cardiac mortality {#sec3.1}
--------------------------------------------------------------

A combined retro- and prospective 52 weeks analysis of ApoE^−/−^TIMP3^−/−^ (n = 32) mice revealed a decreased survival rate when compared to ApoE^−/−^ (n = 32) littermates (p = 0.0002, Cox Test; [Figure 1](#fig1){ref-type="fig"}A), with the first episodes of death observed at week 28 in the ApoE^−/−^TIMP3^−/−^ group. The higher mortality rate in the ApoE^−/−^TIMP3^−/−^ group was independent from gender and no differences between genotypes for specific macroscopic signs of infections including dermatitis or sudden loss of body weight were observed. Since necroscopy of ApoE^−/−^TIMP3^−/−^ mice did not reveal any obvious sign such as bleeding, malignancy or macroscopically visible organ pathology responsible for decreased lifespan, we speculated that mice might suffer from sudden cardiac death.

To test this hypothesis of increased cardiac mortality, we subjected ApoE^−/−^TIMP3^−/−^ mice and ApoE^−/−^ littermates to two different models of cardiac stress: invasive telemetry 24 h ECG and LAD ligation.

We first performed invasive 24 h ECG recordings to investigate the presence of anomalous electrical activity in 32-weeks-old ApoE^−/−^TIMP3^−/−^ and ApoE^−/−^ mice. We observed a higher amount of arrhythmic episodes in ApoE^−/−^TIMP3^−/−^ mice ([Figure 1](#fig1){ref-type="fig"}B) as well as sudden deaths in 4 out of 6 ApoE^−/−^TIMP3^−/−^ male mice during the 7-day registration period (p = 0.06, Fisher Exact test).

In the second model of cardiac stress induction, ApoE^−/−^TIMP3^−/−^ and ApoE^−/−^ mice were subjected to LAD ligation as previously described. In the ApoE^−/−^TIMP3^−/−^ cohort, we observed significantly increased peri-operative mortality compared with ApoE^−/−^ mice with 13/19 mice dying within 24 h of the intervention compared to 2/13 deaths in the ApoE^−/−^ group (p \< 0.0001, Chi-square test, [Figure 1](#fig1){ref-type="fig"}C). Although we cannot measure the occurrence of arrhythmias in this experiment, we did not observe bleeding or other operative complications between the 2 groups. In the few survivors, histological analysis of the ventricle showed extension of the infarction area (p \< 0.05, Student\'s t-test, n = 3--4 per group, [Figure 1](#fig1){ref-type="fig"}D) as well as increased ventricular remodeling and dilatation in the ApoE^−/−^TIMP3^−/−^ mice ([Figure 1](#fig1){ref-type="fig"}D). Invasive cardiac function 4 weeks post LAD ligation revealed reduced systolic and diastolic function in ApoE^−/−^TIMP3^−/^ mice (p \< 0.05 for both, Student\'s t-test, [Figure 1](#fig1){ref-type="fig"}E).

3.2. ApoE^−/−^TIMP3^−/−^ mice show lipid accumulation in heart {#sec3.2}
--------------------------------------------------------------

To gain further insight into structural changes within the heart of ApoE^−/−^TIMP3^−/−^ mice leading to arrhythmias and sudden cardiac death, we performed echocardiographic and histological analyses.

As expected ApoE^−/−^TIMP3^−/−^ mice revealed signs of mild atherosclerosis in both coronary and carotid arteries but no signs of atherothrombosis ([Supplementary Figure S2A--B](#appsec3){ref-type="sec"}). Left ventricular function as measured with echocardiography did not differ between the groups ([Supplementary Figure S2C](#appsec3){ref-type="sec"}).

However, staining of heart sections with Oil Red O revealed focal intracellular accumulation of lipid droplets in the hearts of the ApoE^−/−^TIMP3^−/−^ mice, a phenomenon absent in ApoE^−/−^ mice fed a normal diet at 24 weeks of age ([Figure 2](#fig2){ref-type="fig"}A). When both mouse strains were fed a Western diet for 8 weeks we observed intense and significant higher lipid accumulation in the ApoE^−/−^TIMP3^−/−^ group compared with ApoE^−/−^ mice (p \< 0.05, Student\'s t-test, [Figure 2](#fig2){ref-type="fig"}B).

3.3. Metabolic characterization of ApoE^−/−^TIMP3^−/−^ mice reveals impaired lipid oxidation {#sec3.3}
--------------------------------------------------------------------------------------------

ApoE^−/−^TIMP3^−/−^ mice further showed a complex metabolic phenotype characterized by a trend to lower fasting glucose, a normal Glucose Tolerance Test (GTT) coupled to mild insulin resistance during the Insulin Tolerance Test (\*p \< 0.05, \*\*\*p \< 0.001, Student\'s t test, [Figure 3](#fig3){ref-type="fig"}A--C).

Whole-body indirect calorimetry of ApoE^−/−^TIMP3^−/−^ compared to ApoE^−/−^ mice revealed no difference in the fed state (data not shown). However, because the observed differences in the fasting glucose, we repeated the whole-body indirect calorimetry during 12 consecutive hours of fasting conditions. While no differences were observed in the 0--8 h interval (data not shown), we observed that in the interval from 8 to 12 h of fasting the RER was significantly increased due to significantly reduced lipid oxidation (both p \< 0.05, Student\'s t test, [Figure 3](#fig3){ref-type="fig"}D).

3.4. Metabolomics analysis revealed changes in biomarkers of antioxidant defense, lipid metabolism and sphingolipid pathway {#sec3.4}
---------------------------------------------------------------------------------------------------------------------------

To unveil biomarkers associated to the reduced lifespan and impaired lipid oxidation, we performed metabolomics analysis in ApoE^−/−^ and ApoE^−/−^TIMP3^−/−^. Random Forest analysis of the analyzed biochemicals resulted in a predictive accuracy of 83% in classifying between ApoE^−/−^ and ApoE^−/−^TIMP3^−/−^ mice ([Supplementary Figure S3](#appsec3){ref-type="sec"}). Several metabolites were differently regulated in the ApoE^−/−^TIMP3^−/−^ compared with ApoE^−/−^ littermates ([Supplementary Tables S1 and S2](#appsec3){ref-type="sec"}). In the serum of ApoE^−/−^TIMP3^−/−^ mice, we observed complex modulation of pathways linked to oxidative stress as demonstrated by the depletion of ergothioneine, equol sulfate, cysteine-glutathione disulfide and oxidized glutathione while 2-hydroxybutyrate and 2-aminobutyrate were increased ([Figure 4](#fig4){ref-type="fig"}A,B). ApoE^−/−^TIMP3^−/−^ mice also showed reductions in long-chain monounsaturated FFAs such as 10-nonadecenoate and 10-heptadecenoate, medium-chain acyl-carnitines such as hexanoylcarnitine, medium-chain acyl-glycine (i.e., valerylglycine) and the medium-chain fatty acid marker of beta-oxidation, 3-hydroxydecanoate ([Figure 5](#fig5){ref-type="fig"}A,B). On the other hand, the long-chain acyl-carnitine stearoylcarnitine was significantly elevated in ApoE^−/−^TIMP3^−/−^ mice ([Figure 5](#fig5){ref-type="fig"}A,B). ApoE^−/−^TIMP3^−/−^ mice also showed altered sphingolipid metabolism with increased levels of palmitoyl sphingomyelin, stearoyl sphingomyelin, 1-stearoylglycerol and sphingosin that can be in part connected to increased stearoylcarnitine and its derivatives ([Figure 6](#fig6){ref-type="fig"}A,B).

3.5. Reduced expression of enzymes involved in fatty acid oxidation in ApoE^−/−^TIMP3^−/−^ mice {#sec3.5}
-----------------------------------------------------------------------------------------------

The relative deficiency of long-chain fatty acids along with the concomitant build-up of stearoylcarnitine could reflect a deficiency in stearoyl-CoA desaturase 1 (SCD1) within different tissues. We therefore screened the expression of genes related to the regulation of glucose and lipid metabolism in ApoE^−/−^TIMP3^−/−^ compared with ApoE^−/−^ mice in the liver, skeletal muscle and heart. In the liver, we found reduced mRNA expression for PPARα, SCD1, ACADM, ACADL, ACADVL and FoxO1 ([Supplementary Table S3](#appsec3){ref-type="sec"}). In skeletal muscle, no important differences were found ([Supplementary Table S3](#appsec3){ref-type="sec"}). In the hearts of ApoE^−/−^TIMP3^−/−^ mice, we found significantly decreased expression of PPARα and its targets SCD1, ACADM and a trend for decreased expression of other enzymes involved in fatty acid oxidation such as ACADL and ACADVL ([Table 1](#tbl1){ref-type="table"}). Interestingly, we also found decreased expression of FoxO1, a regulator of oxidative stress and autophagy, and its targets PDK4, ATG5, ATG8, BECN1, LC3, ULK1 ([Table 1](#tbl1){ref-type="table"}).

3.6. Whole heart mRNA sequencing revealed reduced apelin in ApoE^−/−^TIMP3^−/−^ mice {#sec3.6}
------------------------------------------------------------------------------------

To gain insight into the regulation of glucose and lipid metabolism of the heart by TIMP3 we performed mRNA transcriptomic analysis by Next Generation Sequencing (Illumina) of the heart in ApoE^−/−^TIMP3^−/−^ and ApoE^−/−^ littermates. We identified several significantly upregulated and downregulated transcripts from ApoE^−/−^TIMP3^−/−^ compared with ApoE^−/−^ littermates ([Supplementary Figure S4A](#appsec3){ref-type="sec"} and [Supplementary Table S4](#appsec3){ref-type="sec"}). Among the downregulated transcripts, confirmed after qPCR, we found apelin ([Supplementary Figure S4A,B](#appsec3){ref-type="sec"}), which we confirmed to be significantly reduced in heart tissue but not in the epididymal White Adipose Tissue (eWAT), muscle and liver from ApoE^−/−^TIMP3^−/−^ mice by quantitative PCR (\*p \< 0.05, Student\'s t test, [Figure 7](#fig7){ref-type="fig"}A). Apelin blood levels measured by ELISA were shown to be significantly lower in the ApoE^−/−^TIMP3^−/−^ compared with ApoE^−/−^ littermates (\*p \< 0.05, Student\'s t test, [Figure 7](#fig7){ref-type="fig"}B).

3.7. Apelin injection rescues metabolic phenotype in ApoE^−/−^TIMP3^−/−^ mice {#sec3.7}
-----------------------------------------------------------------------------

Finally, we reasoned that injecting apelin in vivo could lead to improvement of metabolic defects observed in ApoE^−/−^TIMP3^−/−^ mice. Indirect calorimetry was performed in fasted ApoE^−/−^TIMP3^−/−^ mice and ApoE^−/−^ littermates after a single intraperitoneal apelin injection; control animals received a matched volume of PBS (per group n = 5--6; values reported in the bar graph were obtained in the interval of prolonged fasting (8--12 h interval)). Apelin injection significantly reduced RER in ApoE^−/−^TIMP3^−/−^ mice (\*\*\*\*p \< 0.001, one-way ANOVA, [Figure 7](#fig7){ref-type="fig"}C) to an extent comparable to PBS-injected ApoE^−/−^ littermates. RER: 0.80 ± 0.02 (ApoE^−/−^ PBS) vs. 0.79 ± 0.02 (ApoE^−/−^TIMP3^−/−^ apelin), not significant, [Figure 7](#fig7){ref-type="fig"}C). Consequently, apelin increased lipid oxidation in ApoE^−/−^TIMP3^−/−^ mice and in ApoE^−/−^ mice, although to a lesser extent (\*\*\*\*p \< 0.001, one-way ANOVA, [Figure 7](#fig7){ref-type="fig"}C).

4. Discussion {#sec4}
=============

The phenotype of the ApoE^−/−^TIMP3^−/−^ mice revealed new, unpredicted findings linking TIMP3 to metabolic flexibility in the heart. Although, compared to control ApoE^−/−^ littermates, the ApoE^−/−^TIMP3^−/−^ mice showed mild increased atherosclerotic plaques and fatty streaks at the aortic roots and the peripheral aorta, the differences were less consistent in the coronary and carotid arteries. It is possible, therefore, that the causes of sudden death are not linked to plaque instability and a possible metabolic origin of the phenotype cannot be excluded. Previous work on the combined ApoE and high-density lipoprotein receptor SR-BI (SR-BI) double knockout revealed early lethality due to increased coronary atherosclerosis combined with lipid accumulation in the left ventricle [@bib29].

The ApoE^−/−^TIMP3^−/−^ mice showed similar globular intracellular lipid accumulation, and when shifted to Western diet, a punctate pattern reminiscent of extracellular lipid deposition [@bib29].

However, differently from the ApoE^−/−^SR-BI^−/−^ model, the ApoE^−/−^TIMP3^−/−^ mice revealed increased lethality at an older age or when subjected to stress conditions like telemetry or experimental myocardial infarction, suggesting that the effect may be partially age- and environment dependent, as already observed with TIMP3 in other cardiovascular models [@bib15; @bib16].

Metabolomics data allows for a hypothesis that explains the increased susceptibility of ApoE^−/−^TIMP3^−/−^ mice to cardiovascular diseases. First, ApoE^−/−^TIMP3^−/−^ mice have defective control of oxidative stress. In particular, they show a state of depletion of dietary antioxidants such as ergothioneine and equol sulfate [@bib30; @bib31] coupled to the decrease of some indicators of oxidation such as cysteine-glutathione disulfide and oxidized glutathione. Similarly, we found increased concentrations of 2-hydroxybutyrate and 2-aminobutyrate, both being derived from the common precursor alpha-ketobutyrate, the levels of which increase when demand for glutathione is high. Since it has been reported that ischemia induces glutathione depletion via osmotic stress [@bib32], it is intriguing to hypothesize that TIMP3 deficiency in the heart mimics the effect of modified lipoproteins and oxysterols to provoke an ischemia-like metabolic alterations at the myocardial level although we cannot exclude the involvement of other tissues [@bib33; @bib34].

Secondly, analysis of sphingolipid metabolism displayed deep perturbations in ApoE^−/−^TIMP3^−/−^ mice. Glutathione depletion has been shown to regulate sphingomyelin metabolism [@bib35], and the loss of an oxidative stress response might be responsible for those alterations. In patients with transient ischemia, and thus increased cardiac stress, increased levels of sphingosine have been found [@bib36]. Further, alterations of sphingolipid metabolism have been reported in rats subjected to LAD ligation [@bib37] and in models of ischemia/reperfusion injury [@bib38; @bib39].

Although, we could not identify ceramide itself in the metabolomics analysis, it is a crucial intermediate of sphingolipid metabolism ([Figure 6](#fig6){ref-type="fig"}B) and has been associated with the dysfunction of the human ether-a-go-go related gene (HERG) K+ channel, which, again, is associated with prolongation of the QT interval and arrhythmias [@bib40]. Therefore, perturbations in sphingolipid metabolism might contribute in increased arrhythmias in the ApoE^−/−^TIMP3^−/−^ mice.

Thirdly, the circulating metabolite profiles suggest that in the face of mild insulin resistance, the loss of TIMP3 in the hypercholesterolemic background is characterized by a block of fatty acid oxidation at the stearoyl-CoA level. This may prompt increased rates of glucose oxidation to support energetic demands. Mice with stearoyl-CoA desaturase 1 deficiency reveal a similar phenotype to ApoE^−/−^TIMP3^−/−^ mice, with increased myocardial glucose utilization and impaired fatty acid oxidation [@bib41]. The limited gene expression screening that we performed in the liver and the muscle confirmed that in this specific context the defective fatty acid oxidation is more prevalent at the cardiovascular level. Therefore, in a TIMP3 deficient state it appears that the heart may be less efficient at compensating for energetic demands during acute stress.

Adult cardiomyocytes produce most energy via fatty acid oxidation (FAO) but retain capacity to readily switch to glucose or other substrate utilization when fatty acid is not available or FAO is compromised [@bib1]. Indeed, when subjecting the myocardium to acute oxidative stress and energy depletion in the model of myocardial infarction, there is an increased mortality, which could be explained by an inability to utilize all metabolic pathways available to produce energy. One may postulate that the lower fasting glucose observed in the ApoE^−/−^TIMP3^−/−^ mice results from a switch to glucose oxidation that impairs a further increase energy production thus ultimately leading to cell death. The reduction PPARα and some of its target genes involved in fatty acid oxidation (such as Hadha Hadhb ACADS ACADM ACADVL) might in part explain the phenotype of the ApoE^−/−^TIMP3^−/−^ mice. In fact, myocardial lipid accumulation and hypoglycemia also characterize the adult mice lacking PPARα [@bib42]. Similarly to the ApoE^−/−^TIMP3^−/−^, deletion of PPARα results in decreased expression of fatty acid β-oxidation genes accompanied by a decrease in fatty acid β-oxidation and a parallel increase in glucose oxidation [@bib42; @bib43; @bib44; @bib45; @bib46]. The ApoE^−/−^TIMP3^−/−^ model may also recall the phenotype characterizing a model of cardiovascular insulin resistance, the Cardiac Insulin Receptor Knockout (CIRKO) mice, in which PPARα and several FAO genes are repressed [@bib47]. Further, we observed a downregulation of Forkhead box protein O1 (FoxO1), which is involved in energy metabolism, but also in autophagy. Coupled with this, its targets ATG5, ATG8, BECN1 and LC3 were also downregulated in ApoE^−/−^TIMP3^−/−^ mice. Decreased autophagy has been related to heart failure and this reduction might contribute to the reduced heart function we observed in our model of post-ischemic heart failure [@bib48].

The occurrence of cardiovascular mortality in ApoE^−/−^TIMP3^−/−^ mice might reflect a complex interaction between metabolic defects and tissue remodeling consequent to increased inflammation and tissue degeneration. Using whole heart mRNA sequencing and subsequent real-time PCR analysis we revealed apelin as a possible mediator of the metabolic effects by TIMP3. In ApoE^−/−^TIMP3^−/−^ mice, we found apelin to be decreased in the circulation as well as downregulated at the myocardial level compared to other sites of expression such as the adipose tissue [@bib49]. Apelin supplementation restored impaired lipid oxidation in ApoE^−/−^TIMP3^−/−^ mice. Therefore, our data provide a molecular clue for the molecular phenotype observed in ApoE^−/−^TIMP3^−/−^ mice.

Apelin has recently been shown to rescue defects in insulin resistance and FAO possibly via regulation of AMPK signaling [@bib27; @bib49]. However, whether a long-term administration of Apelin is sufficient to prevent lipid accumulation and which signaling pathways contribute remains to be investigated.

The effect of TIMP3 on apelin might also explain decreased heart function in post-ischemic heart failure we observed in the ApoE^−/−^TIMP3^−/−^ mice. Patients with left ventricular systolic dysfunction exhibit decreased myocardial apelin expression in the left ventricular wall [@bib50], and experimental in vivo data link apelin to positive inotropic and regenerative effects in both normal hearts and post-ischemic heart failure [@bib51; @bib52; @bib53; @bib54]. We did not test the effects of apelin on experimental myocardial infarction. However, it has previously been shown that in a rat model of post ischemic heart failure, also using the model of LAD ligation, apelin supplementation was able to reduce infarction size [@bib55].

ApoE^−/−^TIMP3^−/−^ mice displayed an impaired oxidative stress response. Chronic treatment of mice with apelin attenuated pressure-overload-induced left ventricular hypertrophy, by increasing the oxidative stress response [@bib56], and decreased ischemia/reperfusion injury by restoring levels of antioxidant defense [@bib57]. Thus, reduced apelin levels found in the ApoE^−/−^TIMP3^−/−^ mice may also be responsible in part for other metabolomics findings of our study. Recently, it has been reported that apelin reduces sphingosine kinase 1 activity in cardiac fibroblasts [@bib58] and might therefore increase levels of sphingosine.

Since reduced apelin levels have also been associated with arrhythmias [@bib59; @bib60], we hypothesize that reduced apelin may contribute to the pro-arrythmogenic phenotype that we observed in the ApoE^−/−^TIMP3^−/−^ model. However, a positive effect of apelin supplementation on arrhythmias in this model remains to be seen.

We have previously reported that loss of TIMP3 has a role in the pathogenesis obesity-associated non-alcoholic fatty liver disease (NAFLD) [@bib8]. We did not measure the lipid content of the liver in this study, but the fact that the livers of ApoE^−/−^TIMP3^−/−^ mice reveal similar defects in the expression of PPARα and FoxO1 targets, including SCD1, suggests that inter-organs crosstalk might be involved in the phenotype observed. Previous studies have shown that SCD1 deficiency is correlated to diet-induced fatty liver disease. NAFLD has also been linked to increased cardiovascular risk, myocardial remodeling and dysfunction as well as prolongation of QTc interval and thus increased risk of arrhythmias [@bib61]. However, we did not observe alterations in hepatic apelin expression suggesting the involvement of different pathways. Overall, we cannot exclude that part of the phenotype is sustained by a liver to heart axis.

Interestingly, metabolomics analysis also revealed an alteration of gut micro biota-derived (host co-) metabolites such as serotonin, N-acetyltryptophan and 3-indoxyl sulfate in the ApoE^−/−^TIMP3^−/−^ ([Supplementary Table 2](#appsec3){ref-type="sec"}). TIMP3 has been shown to regulate lymphocyte populations [@bib62] as well as to mediate colonic epithelial barrier disruption through ADAM17 and might, therefore, be involved in shaping the gut microbiota and regulation of gut microbiota/host interactions, leading to altered immune and metabolic processes. Backhed and colleagues could show that germ-free mice exhibited altered gene expression of enzymes involved in fatty acid oxidation [@bib63]. Therefore, an alteration of the gut microbiota might contribute to the phenotype observed in the ApoE^−/−^TIMP3^−/−^ mice.

5. Conclusion {#sec5}
=============

TIMP3 maintains cardiac metabolic flexibility in conditions of increased stress such as myocardial infarction. Deficiency of TIMP3 results in perturbations of oxidative stress response, sphingolipid pathway and lipid metabolism. Reduced levels of apelin found in ApoE^−/−^TIMP3^−/−^ mice partly explain the defects, and supplementation of apelin rescues the metabolic phenotype by increasing lipid oxidation.
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![**ApoE^−/−^TIMP3^−/−^ animals reveal decreased lifespan, arrhythmias and susceptibility to increased cardiac stress.** A) Combined retro- and prospective survival analysis in a cohort of 64 male and female mice (n = 32 for ApoE^−/−^TIMP3^−/−^ M/F = 12/20 and n = 32 for ApoE^−/−^ M/F = 12/20) over a time period of 12 months (p = 0.0002, Cox Test). B) Telemetry 24 h ECG in 32-weeks-old ApoE^−/−^TIMP3^−/−^ and ApoE^−/−^ mice. We observed a higher amount of arrhythmic episodes in ApoE^−/−^TIMP3^−/−^ as well as sudden deaths in 4 out of 6 male mice during the 7-day registration (p = 0.06, Fisher\'s exact test). C) Increased peri-operative mortality during experimental myocardial infarction by LAD ligation in ApoE^−/−^TIMP3^−/−^ (13/19) compared to ApoE^−/−^ (3/13) (\*\*\*p \< 0.001 by Chi-square test). D) Representative photomicrographs of Masson-Trichrome stained hearts 4 weeks post-LAD ligation showing increased infarction size as confirmed by morphometric quantification of percent total LV circumference. Data are mean ± SEM (\*p \< 0.05 by Student t-test, n = 3--4 per group). E) Reduced systolic (dp/dtmax) and diastolic (dp/dtmin) heart function in ApoE^−/−^TIMP3^−/−^ mice 4 weeks after LAD ligation as measured by Millar Catheter. Data are mean ± SEM (\*p \< 0.05 by Student t-test, n = 4--5 per group).](gr1){#fig1}

![**ApoE^−/−^TIMP3^−/−^ animals show increased deposition of neutral lipids in the heart on normal chow and western diet.** A) Representative sections of myocardium of 6--8 month old ApoE^−/−^TIMP3^−/−^ and ApoE^−/−^ mice on normal chow diet stained with ORO. B) Representative sections and quantification of myocardium from 6 to 8 month old mice fed a Western diet for 8 weeks stained with ORO showing increased lipid deposition in hearts of ApoE^−/−^TIMP3^−/−^ mice. Data are mean ± SEM (\*p \< 0.05, Student t-test, n = 4 per group). Magnification further displays globular intracellular lipid accumulation and a punctate pattern reminiscent of extracellular lipid deposition in ApoE^−/−^TIMP3^−/−^ animals.](gr2){#fig2}

![**Metabolic characterization of ApoE^−/−^TIMP3^−/−^ mice reveals impaired lipid oxidation.** A) Analysis of fasting glucose levels reveals significant reduction in ApoE^−/−^TIMP3^−/−^ mice (\*\*\*p \< 0.001, Student\'s t test, n = 14 for ApoE^−/−^ and n = 6 for ApoE^−/−^TIMP3^−/−^ per group). B) Intraperitoneal Glucose Tolerance test shows no significant differences between the two groups (n = 14 for ApoE^−/−^ and n = 6 for ApoE^−/−^TIMP3^−/−^ per group). C) Mild insulin resistance of ApoE^−/−^TIMP3^−/−^ mice at the Insulin Tolerance Test (\*p \< 0.05, Student\'s t test, n = n = 4 for ApoE^−/−^ and n = 5 for ApoE^−/−^TIMP3^−/−^ per group). D) Indirect calorimetry of ApoE^−/−^TIMP3^−/−^ compared to ApoE^−/−^ mice during 12 consecutive hours of fasting conditions. Data show the interval from 8 to 12 h of fasting. RER was significantly increased and lipid oxidation significantly reduced in ApoE^−/−^TIMP3^−/−^ mice (\*p \< 0.05, Student\'s t test, n = 3--4).](gr3){#fig3}

![**ApoE^−/−^TIMP3^−/−^ mice have impairment of fatty acid metabolism.** A) Metabolomics analysis of the serum shows a decrease in long-chain monounsaturated FFAs, medium-chain acyl-carnitines and medium-chain fatty acid markers in ApoE^−/−^TIMP3^−/−^ animals (\*p ≤ 0.05 and \*\*p \< 0.01, Student\'s t test, n = 6 per group). B) Regulation of MUFA/SUFA balance in mammalian cell lipids by SCD1.](gr4){#fig4}

![**ApoE^−/−^TIMP3^−/−^ mice have loss of defense against oxidative stress.** A) Metabolomics analysis of the serum of ApoE^−/−^TIMP3^−/−^ vs. ApoE^−/−^ animals shows a depletion of dietary antioxidants suggesting a loss of dietary antioxidant and anti-inflammatory chemicals (\*p ≤ 0.05, \*\*p \< 0.01 and \*\*\*p \< 0.001, Student\'s t test, n = 6 per group). B) Glutathione regulation pathway in mammalian cells.](gr5){#fig5}

![**ApoE^−/−^TIMP3^−/−^ mice have disturbed sphingolipid metabolism.** A) Altered sphingolipid metabolism in ApoE^−/−^TIMP3^−/−^ mice revealed by metabolomics analysis of the serum (\*p ≤ 0.05, \*\*p \< 0.01 and \*\*\*p \< 0.001, Student\'s t test, n = 6 per group). B) Sphingolipid metabolism in mammalian cells that can be in part connected to increased stearoylcarnitine and its derivatives.](gr6){#fig6}

![**Loss of TIMP3 leads to disrupted apelin secretion from heart while supplementation can correct some of the metabolic abnormalities in the heart.** A) Apelin expression by qPCR in heart, muscle, adipose tissue and liver reveals a difference between ApoE^−/−^TIMP3^−/−^ and ApoE^−/−^ animals only in the heart (\*p \< 0.05, one-way ANOVA, n = 5 per group). B) Circulating apelin levels measured by ELISA were also found to be reduced in the ApoE^−/−^TIMP3^−/−^ (\*p \< 0.05, Student\'s t test, n = 4 per group). C) Single dose of intraperitoneally injected apelin restores impaired lipid oxidation of ApoE^−/−^TIMP3^−/−^ mice during the prolonged fasting state (interval of 8--12 h) measured by indirect calorimetry. Data are mean ± SEM (\*\*\*\*p \< 0.001, one-way ANOVA, n = 5--6 per group).](gr7){#fig7}

###### 

Loss of TIMP3 leads to altered expression of genes involved in fatty acid metabolism in heart.

  Heart       Fasting                       Fed                                                                                                    
  ----------- ----------------------------- ----------------------------- ------------ ----------------------------- ----------------------------- -----------
  **PPARα**   **0**.**72** ± **0**.**15**   **0**.**36** ± **0**.**02**   **0.04**     0.46 ± 0.04                   0.47 ± 0.06                   0.82
  PPARβ       0.74 ± 0.07                   0.74 ± 0.07                   0.95         0.45 ± 0.03                   0.44 ± 0.03                   0.84
  PPARγ       0.85 ± 0.12                   0.79 ± 0.097                  0.70         0.26 ± 0.03                   0.28 ± 0.04                   0.81
  **FoxO1**   **1**.**27** ± **0**.**38**   **0**.**45** ± **0**.**03**   **0.0495**   **1**.**05** ± **0**.**12**   **0**.**55** ± **0**.**10**   **0.03**
  ERRα        1.92 ± 0.40                   1.41 ± 0.22                   0.30         0.97 ± 0.12                   1.15 ± 0.19                   0.44
  **LXRα**    0.96 ± 0.06                   0.91 ± 0.08                   0.68         **0**.**39** ± **0**.**02**   **0**.**47** ± **0**.**03**   **0.03**
  LXRβ        0.79 ± 0.11                   0.64 ± 0.11                   0.38         0.43 ± 0.06                   0.33 ± 0.03                   0.28
  *Ehhadh*    *0*.*57* *±* *0*.*15*         *0*.*25* *±* *0*.*03*         *0*.*08*     0.06 ± 0.01                   0.09 ± 0.02                   0.12
  *Hadha*     *1*.*02* *±* *0*.*11*         *0*.*80* *±* *0*.*05*         *0*.*09*     0.39 ± 0.02                   0.45 ± 0.04                   0.27
  Hadhb       0.68 ± 0.09                   0.62 ± 0.09                   0.63         0.36 ± 0.02                   0.40 ± 0.06                   0.54
  ACADS       1.29 ± 0.16                   1.34 ± 0.19                   0.84         0.83 ± 0.14                   0.82 ± 0.14                   0.98
  **ACADM**   **1**.**29** ± **0**.**15**   **0**.**79** ± **0**.**13**   **0.047**    0.60 ± 0.05                   0.69 ± 0.11                   0.43
  *ACADVL*    *1*.*21* *±* *0*.*12*         *0*.*90* *±* *0*.*05*         *0*.*07*     0.60 ± 0.10                   0.55 ± 0.06                   0.76
  ACADL       1.08 ± 0.06                   0.97 ± 0.01                   0.12         0.57 ± 0.07                   0.57 ± 0.07                   0.94
  CPT1α       1.10 ± 0.11                   1.12 ± 0.08                   0.89         *0*.*34* *±* *0*.*02*         *0*.*50* ± *0*.*07*           *0.09*
  **PDK4**    **1**.**14** ± **0**.**08**   **0**.**78** ± **0**.**10**   **0.03**     **0**.**03** ± **0**.**01**   **0**.**07** ± **0**.**02**   **0.048**
  **SCD1**    **0**.**94** ± **0**.**04**   **0**.**71** ± **0**.**07**   **0.02**     0.49 ± 0.08                   0.52 ± 0.06                   0.78
  PGC1α       0.57 ± 0.12                   0.56 ± 0.08                   0.98         0.25 ± 0.02                   0.32 ± 0.07                   0.29
  PGC1β       1.41 ± 0.24                   1.44 ± 0.25                   0.93         1.01 ± 0.20                   1.24 ± 0.14                   0.41
  GLUT4       1.48 ± 0.24                   1.54 ± 0.22                   0.85         1.25 ± 0.29                   1.17 ± 0.12                   0.80
  ATG5        0.82 ± 0.08                   0.72 ± 0.04                   0.30         0.76 ± 0.12                   0.73 ± 0.17                   0.86
  **ATG8**    **1**.**08** ± **0**.**36**   **0**.**28** ± **0**.**04**   **0.04**     *0*.*70* *±* *0*.*22*         *0*.*23* *±* *0*.*05*         *0.08*
  **BECN1**   **0**.**74** ± **0**.**08**   **0**.**52** ± **0**.**02**   **0.03**     0.68 ± 0.16                   0.55 ± 0.10                   0.53
  **LC3**     **0**.**99** ± **0**.**17**   **0**.**52** ± **0**.**02**   **0.0498**   0.83 ± 0.09                   0.74 ± 0.08                   0.47
  **ULK1**    **0**.**86** ± **0**.**12**   **0**.**38** ± **0**.**01**   **0.02**     **0**.**80** ± **0**.**13**   **0**.**40** ± **0**.**05**   **0.047**
  GADD 45     1.49 ± 0.42                   2.17 ± 0.35                   0.28         0.27 ± 0.08                   0.36 ± 0.07                   0.45
  SESN1       1.12 ± 0.28                   1.23 ± 0.12                   0.73         0.38 ± 0.12                   0.51 ± 0.02                   0.36
  SESN2       0.88 ± 0.15                   0.72 ± 0.02                   0.37         0.43 ± 0.09                   0.51 ± 0.03                   0.42
  SOD1        1.10 ± 0.10                   1.33 ± 0.03                   0.17         0.64 ± 0.06                   0.67 ± 0.05                   0.71
  SOD2        1.07 ± 0.03                   1.08 ± 0.12                   0.95         0.97 ± 0.15                   0.87 ± 0.10                   0.62
  CAT         0.52 ± 0.16                   0.30 ± 0.02                   0.22         0.18 ± 0.06                   0.13 ± 0.02                   0.42

Gene expression by qPCR in the heart of ApoE^−/−^Timp3^−/−^ and ApoE^−/−^ mice in the fasting and fed state. Data are mean ± SEM (Bold indicates p \< 0.05 and italics 0.05 \< p \< 0.1, Student\'s t test, n = 4--5 per group).
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